Tech Company Inital Public Offerings
Talaris Therapeutics IPO
Talaris Therapeutics, operating out of Louisville, debuted as a public company on 5/7/2021.
Transaction Overview
Company Name
Announced On
5/7/2021
Transaction Type
IPO
Amount
$149,600,000
Proceeds Purpose
Use of proceeds for the Talaris Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
201 East Jefferson St. 110B
Louisville, KY 40202
USA
Louisville, KY 40202
USA
Phone
Website
Email Address
Overview
Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Requadt
Chief Financial Officer
Gregg Beloff
Chief Marketing Officer
Nancy Krieger
Chief Scientific Officer
Suzanne Ildstad
Vice President
Mary West
VP - Finance
Keith McCormick
VP - Human Resources
Roderick Purdy
VP - Manufacturing
Devin Blass
VP - Operations
Suzanne Tollerud
VP - Product Management
Eric Gornstein
VP - Regulatory Affairs
Andrew Beavis
VP - Regulatory Affairs
Sue Graumlich
Browse more venture capital transactions:
Prev: 5/7/2021: Recharge Ecommerce venture capital transaction
Next: 5/7/2021: Metafy venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs